Quest Diagnostics Inc vs United States Oil ETF — how do they compare? Quest Diagnostics Inc trades at $238.51 (market cap $26.21B), while United States Oil ETF trades at $127.17. The key difference: Quest Diagnostics Inc pays a 1.45% dividend while United States Oil ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, United States Oil ETF nearer its low. Which is the better fit depends on your goals.
| DGX | USO | |
|---|---|---|
Market Cap | $26.21B | — |
Sector | Health | — |
52-Week High | $238.50 | $152.96 |
52-Week Low | $173.49 | $66.17 |
Enterprise Value | $31.97B | — |
Dividend Yield | 1.45% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
USO trades at $127.36, up 1.14% with bullish technical signals from moving averages. The stock faces mixed sentiment as oil markets balance supply disruptions from Middle East tensions against OPEC's downward demand revisions. Technical indicators show strong momentum with ADX signaling trend strength while RSI remains neutral, suggesting room for further movement.
The outlook remains volatile with geopolitical risks driving price action. Upside potential exists if Middle East supply constraints persist, but demand destruction concerns and inventory builds present headwinds. Investors should monitor Strait of Hormuz developments and EIA inventory data for directional catalysts.
Trailing returns across standard periods
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →